BioLegend acquires shares of Covance Antibody Services -
BioLegend, Inc. (BioLegend) acquired the shares of Covance Antibody Services Inc., a business unit of Covance located in Dedham, Massachusetts, on August 29 2014. the business unit Covance antibody develops and manufactures antibodies and research reagents for neuroscience, immunopathology, cell biology, Epitope Tag detection and immunohistochemistry. These products, including in vitro diagnostic (IVD) for IHC antibodies are well suited to complement and enhance the current selection of BioLegend research reagents. Covance antibodies can customers expect the same support and superior customer exceptional value with these products than existing BioLegend customers.
"We are delighted to add people and antibody products at Covance BioLegend team," said Gene Lay, President and CEO, BioLegend. As neuroinflammation and neurodegeneration become subjects of increasingly important, Covance antibody is an ideal strategic fit in BioLegend's commitment to promoting the discovery in neuroscience. with the addition of a world-class R & D team and more than 0 antibody products for emerging and important target countries in this area, BioLegend is positioned to become a leader in research in neuroscience and immunology.
"the addition of neuroscience and IHC antibody tools accelerated discovery means our catalog for our current and new customers. We hope to bring our quality, support and value well known in the immunology community neuroscience researchers worldwide, "said Gene Lay.
EmoticonEmoticon